Design of the PF-ILD trial: a double-blind, randomised, placebo-controlled phase III trial of nintedanib in patients with progressive fibrosing interstitial lung disease

2017187 citationsJournal Articlegold Open Access

Authors

NCT02999178.

Good health and well-being

Published in: BMJ Open Respiratory Research

Volume 4, Issue 1, pp. e000212-e000212

Field-Weighted Citation Impact: 19.63